Bionano Genomics (BNGO)
(Delayed Data from NSDQ)
$0.33 USD
-0.01 (-2.16%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $0.33 0.00 (1.23%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.33 USD
-0.01 (-2.16%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $0.33 0.00 (1.23%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Zacks News
Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Bionano Genomics (BNGO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
by Zacks Equity Research
Bionano Genomics (BNGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AbCellera Biologics Inc. (ABCL) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Bionano Genomics, Inc. (BNGO) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
by Zacks Equity Research
QIAGEN's (QGEN) NGS interpretation software, QCI Interpret, now covers the whole exome due to additional AI capabilities.
Bionano Genomics, Inc. (BNGO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -37.78% and 6.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?
by Zacks Equity Research
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -33.33% and 1.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bionano Genomics, Inc. (BNGO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Bionano Genomics, Inc. (BNGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bionano Genomics, Inc. (BNGO) and Amarin (AMRN) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Bionano Genomics (BNGO) This Year?
by Zacks Equity Research
Here is how Bionano Genomics, Inc. (BNGO) and Aziyo Biologics, Inc. (AZYO) have performed compared to their sector so far this year.
Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bionano Genomics, Inc. (BNGO) and Exact Sciences (EXAS) have performed compared to their sector so far this year.
Bears are Losing Control Over Bionano Genomics, Inc. (BNGO), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Bionano Genomics, Inc. (BNGO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 8.33% and 7.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -10% and 7.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 23.08% and 8.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Bionano Genomics, Inc. (BNGO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -37.50% and 5.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Bionano (BNGO) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Bionano (BNGO) stock based on the movements in the options market lately.